All Pharmacy Pearls

Introduction

  • Vancomycin and piperacillin-tazobactam are combined for broad-spectrum antibiotic coverage including

    • MRSA and Pseudomonas in hospitalized patients.

  • AKI, often as acute tubular necrosis, is a known complication of vancomycin, especially with higher doses and

    • co-administration of nephrotoxic drugs.

  • Piperacillin-tazobactam alone has minimal nephrotoxicity (<1%); its nephrotoxicity is usually due to acute

    • interstitial nephritis.

  • Reported AKI rates vary in literature based on AKI definition and target population.
  • Both drugs affect OAT1/3 transporters in the kidney, which are crucial for creatinine clearance and are

    • especially significant in patients with CKD.

Clinical Detail

Comparison of vancomycin and piperacillin-tazobactam dosing, administration, pharmacokinetics/pharmacodynamics, and adverse effects.

PropertyVancomycinPiperacillin-tazobactam
DoseDepends on infection and PK/PD target
General dosing for systemic infections: IV 15–20 mg/kg IV Q8–12H for systemic infections		Standard infusion: 3.375 g IV Q6H over 30 min
Antipseudomonal: 4.5 g IV Q6–8H over 30 min
Extended infusion: 4.5 g IV then 3.375–4.5 g over 4 hours Q8H
AdministrationAdminister IV over ≥60 minutes at concentrations ≤5 mg/mL to reduce the risk of vancomycin infusion reactionStandard infusion: Infuse over 30 min
Extended infusion: Infuse loading dose over 30 min, start maintenance dose four hours later infused over 4 hours
PK/PDNegligible oral bioavailability
T1/2 = 4–6 hours
Renally eliminated (40–100% unchanged)
AUC:MIC dependent kinetics, PK/PD target AUC/MIC ≥400 µg/mL; surrogate serum trough concentrations often used		T1/2 = 0.7–1.2 hours
Renally eliminated (80% unchanged)
Dose adjust at CrCl<40
T>MIC dependent kinetics, prolonged infusions enhance efficacy
Adverse EffectsNephrotoxicity
Ototoxicity
Vancomycin-infusion reaction (flushing, hypotension, tachycardia)		GI upset (diarrhea, nausea, constipation)
Headache

Evidence

Selected studies evaluating acute kidney injury (AKI) risk with piperacillin-tazobactam- and vancomycin-containing regimens.

Author, yearDesign / sample sizeIntervention & ComparisonAKI definitionOutcome
Sanz et al., 2002Prospective, multi-center (n = 969)Amikacin+cefepime vs. amikacin+piperacillin-tazobactamIncreased SCr ≥50% from baselineNo difference in severe nephrotoxicity between amikacin+piperacillin-tazobactam vs. amikacin+cefepime
Karino et al., 2016Retrospective cohort and nested case-control studies (n = 320)Vancomycin+piperacillin-tazobactam standard infusion vs. vancomycin+piperacillin-tazobactam extended-infusionRIFLE criteria; AKIN criteria; Vancomycin consensus guideline definition–

Conclusions

    Since 2011, evidence indicates combined vancomycin+ piperacillin-tazobactam may be nephrotoxic.

    Most studies were retrospective, defining nephrotoxicity by creatinine-based AKI.

    Recent data show this AKI definition doesn’t align with severe AKI outcomes (hemodialysis/mortality).

    Non-tubular secretion biomarkers (Cystatin C, BUN) didn’t show the same AKI increase.

    Despite >50 studies linking the drug combo with AKI, some expert report true renal risk is likely minimal.

    In emergencies, timely antibiotic use is vital; nephrotoxicity concerns shouldn’t delay this combo, especially for short use.

    (Caroline Rosario & [email protected]

References

    Micromedex [Electronic version].Greenwood Village, CO: Truven Health Analytics. Retrieved October 4, 2023, from

    http://www.micromedexsolutions.com/

    VANCOMYCIN HYDROCHLORIDE [package insert]. Rockford, IL: Mylan Institutional LLC; Jul, 2018.

    Blair M, Côté JM, Cotter A, Lynch B, Redahan L, Murray PT. Nephrotoxicity from Vancomycin Combined with Piperacillin-Tazobactam: A

    Comprehensive Review. Am J Nephrol. 2021;52(2):85-97. doi: 10.1159/000513742.

    Pill MW, O’Neill CV, Chapman MM, Singh AK. Suspected acute interstitial nephritis induced by piperacillin-tazobactam.

    Pharmacotherapy. 1997 Jan-Feb;17(1):166-9..

    Li H, Yang Q, Gui M, Ding L, Yang L, Sun H, Li Z. Changes of renal transporters in the kinetic process of VCM-induced nephrotoxicity in

    mice. Toxicol Res (Camb). 2021 Jun 9;10(4):687-695. doi: 10.1093/toxres/tfab048. PMID: 34484661; PMCID: PMC8403606.

    Giuliano CA, Patel CR, Kale-Pradhan PB. Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development

    of Acute Kidney Injury? A Meta-analysis. Pharmacotherapy. 2016 Dec;36(12):1217-1228. doi: 10.1002/phar.1851.

    Boucher, H. (2023) Piperacillin-tazobactam, Sanford Guide Web Edition. Available at: https://webedition.sanfordguide.com/en/drug-

    information/antibacterial-agents/penicillins/anti-pseudomonal-penicillins/piperacillin-tazobactam (Accessed: 12 October 2023).

    Yang S, Liu Z, Wang C, Wen S, Meng Q, Huo X, Sun H, Ma X, Peng J, He Z, Liu K. Piperacillin enhances the inhibitory effect of tazobactam

    on β-lactamase through inhibition of organic anion transporter 1/3 in rats. Asian J Pharm Sci. 2019 Nov;14(6):677-686. doi:

  • 1016/j.ajps.2018.11.003.

    • Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Sörgel F. Inhibition of flucloxacillin tubular renal secretion by piperacillin.

    Br J Clin Pharmacol. 2008 Nov;66(5):648-59. doi: 10.1111/j.1365-2125.2008.03266.x.

  • Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP. Are vancomycin trough concentrations adequate for optimal

    • dosing? Antimicrob Agents Chemother. 2014;58(1):309-16. doi: 10.1128/AAC.01653-13.

  • Alvarez-Arango S, Ogunwole SM, Sequist TD, Burk CM, Blumenthal KG. Vancomycin Infusion Reaction – Moving beyond “Red Man

    • Syndrome”. N Engl J Med. 2021 Apr 8;384(14):1283-1286. doi: 10.1056/NEJMp2031891. Epub 2021 Apr 3.

  • Vallon V, Eraly SA, Rao SR, Gerasimova M, Rose M, Nagle M, Anzai N, Smith T, Sharma K, Nigam SK, Rieg T. A role for the organic anion

    • transporter OAT3 in renal creatinine secretion in mice. Am J Physiol Renal Physiol. 2012 May 15;302(10):F1293-9. doi:

  • 1152/ajprenal.00013.2012. Epub 2012 Feb 15. PMID: 22338083; PMCID: PMC3362066.
  • Sanz MA, López J, Lahuerta JJ, Rovira M, Batlle M, Pérez C, Vázquez L, Julià A, Palau J, Gutiérrez M, Capote FJ, Ramos F, Benlloch L, Larrea

    • L, Jarque I; Spanish PETHEMA Group. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in

    haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother. 2002

    Jul;50(1):79-88. doi: 10.1093/jac/dkf087. PMID: 12096010.

  • Watkins RR, Deresinski S. Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy-

    • What Is the Clinician to Do? Clin Infect Dis. 2017 Nov 29;65(12):2137-2143. doi: 10.1093/cid/cix675.

  • Karino S, Kaye KS, Navalkele B, Nishan B, Salim M, Solanki S, Pervaiz A, Tashtoush N, Shaikh H, Koppula S, Martin ET, Mynatt RP, Murray KP,

    • Rybak MJ, Pogue JM. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-

    Tazobactam: Opportunities for Antimicrobial Stewardship. Antimicrob Agents Chemother. 2016 May 23;60(6):3743-50. doi:

  • 1128/AAC.03011-15.
  • Hammond DA, Smith MN, Li C, Hayes SM, Lusardi K, Bookstaver PB. Systematic Review and Meta-Analysis of Acute Kidney Injury

    • Associated with Concomitant Vancomycin and Piperacillin/tazobactam. Clin Infect Dis. 2017 Mar 1;64(5):666-674. doi:

  • 1093/cid/ciw811. Epub 2016 Dec 10. PMID: 27940946.
  • Rutter WC, Cox JN, Martin CA, Burgess DR, Burgess DS. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-

    • Tazobactam or Cefepime. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e02089-16. doi: 10.1128/AAC.02089-16. Erratum in:

    Antimicrob Agents Chemother. 2017 Mar 24;61(4): PMID: 27895019; PMCID: PMC5278703.

Tags:vancomycin piperacillin-tazobactam acute kidney injury cefepime

Source PDF

vanc-zosyn-aki.pdf